Rocket Pharmaceuticals Stock Operating Margin

RCKT Stock

USD 14.10 0.01 0.07%

Rocket Pharmaceuticals fundamentals help investors to digest information that contributes to Rocket Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Rocket Stock. The fundamental analysis module provides a way to measure Rocket Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Rocket Pharmaceuticals stock.

Last Reported

Projected for Next Year

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Rocket Pharmaceuticals Company Operating Margin Analysis

Rocket Pharmaceuticals' Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.

Operating Margin

Operating Income

Revenue

100

More About Operating Margin | All Equity Analysis

Rocket Operating Margin Driver Correlations

Understanding the fundamental principles of building solid financial models for Rocket Pharmaceuticals is extremely important. It helps to project a fair market value of Rocket Stock properly, considering its historical fundamentals such as Operating Margin. Since Rocket Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Rocket Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Rocket Pharmaceuticals' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Net Tangible Assets	Long Term Debt	Short Long Term Debt	Short Term Investments	Capital Surpluse	Property Plant Equipment	Long Term Debt Total	Net Invested Capital	Net Working Capital	Long Term Investments	Capital Stock
Total Assets		0.95	-0.24	-0.77	-0.69	0.36	0.63	0.99	0.69	0.89	0.99	0.64	0.01	0.79	0.92	0.75	-0.92	0.97	0.95	0.39	0.83
Total Stockholder Equity	0.95		-0.14	-0.7	-0.81	0.31	0.56	0.94	0.66	0.97	0.96	0.61	-0.14	0.9	0.87	0.86	-0.95	0.97	0.95	0.42	0.87
Current Deferred Revenue	-0.24	-0.14		0.23	0.05	-0.95	-0.03	-0.18	-0.13	-0.09	-0.17	-0.04	-0.17	0.03	-0.24	-0.12	0.11	-0.18	-0.11	-0.49	-0.17
Net Debt	-0.77	-0.7	0.23		0.2	-0.17	-0.33	-0.83	-0.6	-0.54	-0.79	-0.38	0.05	-0.34	-0.62	-0.36	0.6	-0.74	-0.81	0.15	-0.36
Retained Earnings	-0.69	-0.81	0.05	0.2		-0.34	-0.41	-0.62	-0.5	-0.86	-0.69	-0.45	0.2	-0.93	-0.78	-0.95	0.83	-0.75	-0.66	-0.72	-0.94
Accounts Payable	0.36	0.31	-0.95	-0.17	-0.34		0.12	0.27	0.21	0.31	0.29	0.12	0.06	0.24	0.39	0.36	-0.3	0.32	0.22	0.72	0.41
Total Liab	0.63	0.56	-0.03	-0.33	-0.41	0.12		0.63	0.49	0.53	0.58	0.65	0.49	0.58	0.52	0.39	-0.58	0.64	0.64	0.23	0.51
Total Current Assets	0.99	0.94	-0.18	-0.83	-0.62	0.27	0.63		0.67	0.87	0.99	0.67	-0.01	0.75	0.87	0.69	-0.88	0.95	0.95	0.26	0.75
Short Term Debt	0.69	0.66	-0.13	-0.6	-0.5	0.21	0.49	0.67		0.52	0.67	0.1	0.19	0.58	0.78	0.53	-0.74	0.77	0.79	0.24	0.64
Common Stock	0.89	0.97	-0.09	-0.54	-0.86	0.31	0.53	0.87	0.52		0.9	0.62	-0.21	0.95	0.81	0.89	-0.93	0.91	0.87	0.51	0.88
Net Tangible Assets	0.99	0.96	-0.17	-0.79	-0.69	0.29	0.58	0.99	0.67	0.9		0.64	-0.06	0.79	0.91	0.75	-0.92	0.96	0.95	0.34	0.81
Long Term Debt	0.64	0.61	-0.04	-0.38	-0.45	0.12	0.65	0.67	0.1	0.62	0.64		0.18	0.54	0.44	0.43	-0.51	0.55	0.54	0.17	0.43
Short Long Term Debt	0.01	-0.14	-0.17	0.05	0.2	0.06	0.49	-0.01	0.19	-0.21	-0.06	0.18		-0.13	0.07	-0.12	0.02	0.03	0.03	-0.07	-0.06
Short Term Investments	0.79	0.9	0.03	-0.34	-0.93	0.24	0.58	0.75	0.58	0.95	0.79	0.54	-0.13		0.78	0.92	-0.91	0.86	0.81	0.58	0.92
Capital Surpluse	0.92	0.87	-0.24	-0.62	-0.78	0.39	0.52	0.87	0.78	0.81	0.91	0.44	0.07	0.78		0.83	-0.91	0.91	0.86	0.53	0.91
Property Plant Equipment	0.75	0.86	-0.12	-0.36	-0.95	0.36	0.39	0.69	0.53	0.89	0.75	0.43	-0.12	0.92	0.83		-0.88	0.82	0.75	0.63	0.94
Long Term Debt Total	-0.92	-0.95	0.11	0.6	0.83	-0.3	-0.58	-0.88	-0.74	-0.93	-0.92	-0.51	0.02	-0.91	-0.91	-0.88		-0.96	-0.92	-0.5	-0.9
Net Invested Capital	0.97	0.97	-0.18	-0.74	-0.75	0.32	0.64	0.95	0.77	0.91	0.96	0.55	0.03	0.86	0.91	0.82	-0.96		0.99	0.4	0.86
Net Working Capital	0.95	0.95	-0.11	-0.81	-0.66	0.22	0.64	0.95	0.79	0.87	0.95	0.54	0.03	0.81	0.86	0.75	-0.92	0.99		0.24	0.78
Long Term Investments	0.39	0.42	-0.49	0.15	-0.72	0.72	0.23	0.26	0.24	0.51	0.34	0.17	-0.07	0.58	0.53	0.63	-0.5	0.4	0.24		0.73
Capital Stock	0.83	0.87	-0.17	-0.36	-0.94	0.41	0.51	0.75	0.64	0.88	0.81	0.43	-0.06	0.92	0.91	0.94	-0.9	0.86	0.78	0.73

Click cells to compare fundamentals

A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.

Competition

Predict Rocket Pharmaceuticals

Operating Profit Margin Over Time

Based on the recorded statements, Rocket Pharmaceuticals has an Operating Margin of 0.0%. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The operating margin for all United States stocks is 100.0% lower than that of the firm.

Rocket Operating Margin Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Rocket Pharmaceuticals' direct or indirect competition against its Operating Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Rocket Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Rocket Pharmaceuticals by comparing valuation metrics of similar companies.

Rocket Pharmaceuticals is currently under evaluation in operating margin category among its peers.

Rocket Pharmaceuticals Current Valuation Drivers

We derive many important indicators used in calculating different scores of Rocket Pharmaceuticals from analyzing Rocket Pharmaceuticals' financial statements. These drivers represent accounts that assess Rocket Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Rocket Pharmaceuticals' important valuation drivers and their relationship over time.

	2019	2020	2021	2022	2023	2024 (projected)
Market Cap	1.1B	3.0B	1.4B	1.3B	2.5B	2.6B
Enterprise Value	977.5M	2.8B	1.2B	1.2B	2.5B	2.6B

Rocket Pharmaceuticals ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Rocket Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Rocket Pharmaceuticals' managers, analysts, and investors.

Environmental

Governance

Social

Rocket Fundamentals

	Return On Equity	-0.59
	Return On Asset	-0.34
	Current Valuation	1.08 B
	Shares Outstanding	91.16 M
	Shares Owned By Insiders	3.40 %
	Shares Owned By Institutions	96.60 %
	Number Of Shares Shorted	11.9 M
	Price To Book	3.90 X
	EBITDA	(236.62 M)
	Net Income	(245.59 M)
	Cash And Equivalents	321.37 M
	Cash Per Share	4.87 X
	Total Debt	25.04 M
	Debt To Equity	0.06 %
	Current Ratio	13.41 X
	Book Value Per Share	3.62 X
	Cash Flow From Operations	(194.92 M)
	Short Ratio	14.81 X
	Earnings Per Share	(2.73) X
	Price To Earnings To Growth	0.03 X
	Target Price	46.79
	Number Of Employees	268
	Beta	1.09
	Market Capitalization	1.29 B
	Total Asset	566.34 M
	Retained Earnings	(959.37 M)
	Working Capital	329.72 M
	Net Asset	566.34 M

About Rocket Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Rocket Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Rocket Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Rocket Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Rocket Stock Analysis

When running Rocket Pharmaceuticals' price analysis, check to measure Rocket Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rocket Pharmaceuticals is operating at the current time. Most of Rocket Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Rocket Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rocket Pharmaceuticals' price. Additionally, you may evaluate how the addition of Rocket Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC